KCKenneth D. Chavin

Kenneth D. Chavin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth D. Chavin has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study

    by James N. Fleming, David J. Taber, Nicole A. Weimert, Satish Nadig, John W. McGillicuddy, Charles F. Bratton, Prabhakar K. Baliga, Kenneth D. Chavin

    Background: With the advent of effective antivirals against cytomegalovirus (CMV), use of CMV hyperimmune globulin (HIG) has decreased. Although antiviral prophylaxis in patients at high risk for CMV is effective, many patients still have late infection, never developing antibodies sufficient to achieve immunity. Utilizing a combination of antiviral and CMV HIG may allow patients to achieve immunity and decrease late CMV infections.Methods: This was a prospective randomized, open‐label, pilot study comparing valganciclovir (VGCV) prophylaxis for 200 days vs VGCV for 100 days followed by CMV HIG in abdominal transplant recipients at high risk for CMV. The primary outcome was a comparison of late CMV disease.Results: Forty patients were randomized to VGCV for 200 days (n = 20) or VGCV for 100 days followed by 3 doses of monthly CMV HIG (n = 20). Numerically, more overall CMV infections occurred in the CMV HIG group (45 vs 20%, P = .09). No differences in overall CMV infections or late CMV disease were seen between groups (20% vs 15%, P = 1.00 and 0 vs 0, P = 1.00). All CMV disease occurred within 200 days, with 63% occurring while patients were on VGCV. No differences were found in toxicities, graft function, or rejection between groups. Patients with CMV infection at any time had a higher body weight than those who did not have an infection (82 vs 95 kg, P = .049).Conclusion: Use of CMV HIG sequentially with prophylaxis may be an effective and affordable prophylactic regimen in abdominal transplant recipients at high risk for CMV, and warrants larger prospective study. Increased monitoring for patients with obesity may be warranted.


  • Open Access

    The Current State of Liver Transplantation in the United States

    by S. A. Fayek, C. Quintini, K. D. Chavin, C. L. Marsh


  • Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll‐Like Receptor 4 in Mice

    by Alton G. Sutter, Arun P. Palanisamy, Julie H. Lench, Scott Esckilsen, Tuoyu Geng, David N.B. Lewin, Lauren A. Cowart, Kenneth D. Chavin

    Nonalcoholic steatohepatitis (NASH) is currently the third most common cause of end stage liver disease necessitating transplantation. The question remains how inflammation and NASH develop in the setting of nonalcoholic fatty liver disease (NAFLD) and steatosis. Understand the roles of toll‐like receptor 4 (TLR4) and dietary fats in the development of hepatic inflammation. Wild‐type and TLR4 KO mice were fed a standard high fat diet (LD), a high saturated fat diet (MD), or an isocaloric control diet (CD). Sera and tissue were analyzed for development of hepatic steatosis, inflammation, and injury. MD induced features of hepatic steatosis and inflammation in wild‐type, but not in TLR4 KO, mice. TLR4 KO prevented MD induced increases in NAFLD activity scores, serum alanine aminotransferase levels, and inflammatory cytokine expression. Inflammatory cell infiltration and cytokine expression were also lower in the TLR4 KO mice livers than wild‐type mice fed MD. Hepatic expression of Collagen I transcripts and collagen deposition were also decreased in the TLR4 KO MD animals. Results show that TLR4 plays a critical role in the effects of dietary fat composition on the development of hepatic steatosis, inflammation, and injury consistent with nonalcoholic steatohepatitis. J. Cell. Biochem. 117: 1613–1621, 2016.


  • Clinical Outcomes and Costs Associated with In-hospital Biliary Complications After Liver Transplantation: a Cross-Sectional Analysis

    by Arun P. Palanisamy, D. J. Taber, A. G. Sutter, S. N. Nadig, J. E. Dowden, J. W. McGillicuddy, P. K. Baliga, K. D. Chavin


  • Intereukin-10 and Kupffer cells protect steatotic mice livers from ischemia-reperfusion injury

    by Alton G. Sutter, Arun P. Palanisamy, Justin D Ellet, Michael G Schmidt, Rick G Schnellmann, Kenneth D. Chavin

    Steatotic livers are more sensitive to ischemia/reperfusion (I/R) and are thus routinely rejected for transplantation because of their increased rate of primary nonfunction (PNF). Lean livers have less I/R-induced damage and inflammation due to Kupffer cells (KC), which are protective after total, warm, hepatic I/R with associated bowel congestion. This protection has been linked to KC-dependent expression of the potent anti-inflammatory cytokine interleukin-10 (IL-10). We hypothesized that pretreatment with exogenous IL-10 would protect the steatotic livers of genetically obese (ob/ob) mice from inflammation and injury induced by I/R. Lean and ob/ob mice were pretreated with either IL-10 or liposomally-encapsulated bisphosphonate clodronate (shown to deplete KC) prior to total, warm, hepatic I/R. IL-10 pretreatment increased survival of ob/ob animals at 24 hrs post-I/R from 30% to 100%, and significantly decreased serum ALT levels. At six hrs post-I/R, IL-10 pretreatment increased IL-10 mRNA expression, but suppressed up-regulation of the pro-inflammatory cytokine IL-1β mRNA. However, ALT levels were elevated at six hrs post-I/R in KC-depleted animals. These data reveal that pretreatment with IL-10 protects steatotic livers undergoing I/R, and that phagocytically active KC retain a hepatoprotective role in the steatotic environment.


  • Open Access

    Health care provider perception of chronic kidney disease: knowledge and behavior among African American patients

    by Abby S Kazley, Emily E Johnson, Kit N Simpson, Kenneth D Chavin, Prabhakar Baliga

    Chronic Kidney disease (CKD) is prevalent in the population, but also disproportionately affects African Americans. Disparities in care of chronic kidney disease and transplant for African Americans have also been reported. The purpose of this study is to determine the knowledge and reactions of chronic kidney disease patients regarding their disease, as perceived by nephrologists and clinic nurses in South Carolina.


  • Predictability of a 30-Day Readmission Risk Model in Kidney Transplant Recipients.

    by D. Taber, N. Pilch, C. Bratton, J. McGillicuddy, T. Srinivas, K. Chavin, P. Baliga

    Background: 30-day readmissions (30DRA) are a highly scrutinized surrogate measure of healthcare quality, with Medicare penalizing hospitals for high 30DRAs for certain admission types. Thus, understanding important factors associated with 30DRA may lead to improved risk assessment, resource allocation and reduced events. Methods: This was a large-scale retrospective analysis with the primary aim of developing a predictive risk model for 30DRA. Adult kidney transplant (KTX) recipients from 2005-12 were included; baseline donor and recipient data was collected, along with detailed in-hospital clinical and cost data. Risk models were developed using backward conditional binary logistic regression and tested for predictability using ROC curves. Results: 1,176 KTX patients were included, of which 130 (11%) had 30DRA. Univariate risk factors for 30DRA included recipient comorbidities, donor factors, transplant factors and index hospitalization data. The initial risk model included 27-variables and demonstrated significant predictability (C-statistic 0.77, NPV 71%, PPV 67%, Figure 1). Through backwards elimination, this model was reduced to a 9-variable risk model (Table 1), which performed as well as the 27-variable model (C-statistic 0.75, NPV 66%, PPV 67%, Figure 2). The most significant predictors of 30DRA included recipient sociodemographics, induction therapy, DGF and a number of index hospitalization data (blood pressures and costs), while donor factors were not significantly associated with 30DRA. Conclusion: 30-Day readmissions are common after KTX. A risk model that includes recipient sociodemographics, induction therapy, DGF and index hospitalization data is significantly predictive of readmission. This risk model, if validated, may be utilized to focus resources on high-risk patients and reduce these events.

  • Knocking Out TLR4 Protects Mice From Non Alcoholic SteatoHepatitis But Not Obesity.

    by A. Palanisamy, A. Sutter, K. Chavin

    The etiology of non-alcoholic fatty liver disease (NAFLD) progression, and why some patients develop non-alcoholic steatohepatitis (NASH) vs. uncomplicated NAFLD, is not well understood. Obesity and NAFLD are thought to be associated with high circulating levels of leptin; however, the role of leptin in NASH has been controversial. We evaluated the long-term effects of steatosis on the livers of aleptinemic (ob/ob) mice. Secondly, as ob/ob mice are known to have elevated circulating levels of endotoxin secondary to increased intestinal permeability, we evaluated to role of toll-like receptor 4 (TLR4) in the development of hepatic sequelae in these animals. At 20 weeks of age ob/ob animals displayed grossly steatotic livers, but also features of early stage NASH including hepatocellular ballooning and numerous necroinflammatory foci with associated changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT). TLR4 knock out did not affect the development of obesity or steatosis in ob/ob mice but protected from hepatitis and liver injury as evidenced by inflammatory cytokines. The data presented here indicate that steatohepatitis develops in the absence of leptin, and that TLR4 is integral to the development NASH secondary to hyperphagia and inflammation.

  • Risk Factors for Development of Opportunistic Infections in Pediatric Renal Transplant Patients.

    by C. Jordan, D. Taber, N. Pilch, J. Fleming, M. Oliver, J. Connelly, S. Nadig, A. Lin, J. McGillicuddy, I. Shatat, et al.